Review on the Influence of Protocol Design on Clinical Outcomes in Rheumatoid Arthritis Treated with Rituximab

Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Current Understanding of Rheumatoid Arthritis Therapy

(2012) I Colmegna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study

(2012) E. C. KEYSTONE et al.   JOURNAL OF RHEUMATOLOGY

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

(2011) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial

(2011) BOULOS HARAOUI et al.   JOURNAL OF RHEUMATOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

(2011) P. Emery et al.   RHEUMATOLOGY

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) R. Knevel et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) C. Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment

(2010) E. M. Vital et al.   ARTHRITIS AND RHEUMATISM

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

(2010) R. F. van VOLLENHOVEN et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy

(2010) C. Deighton et al.   RHEUMATOLOGY

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

Rationale of using different biological therapies in rheumatoid arthritis

(2010) Matthias Geyer et al.   ARTHRITIS RESEARCH & THERAPY

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

(2009) A Finckh et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

(2009) R. M. Fleischmann   ARTHRITIS AND RHEUMATISM

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

(2008) Y K O Teng et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders

(2008) Rogier M. Thurlings et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET